On January 8, 2020, Progentec Diagnostics, Inc. closed the transaction. The company has issued 5,000,000 preferred shares for the gross proceeds $5,000,000 funding led by Plains Venture Partners I, L.P., Oklahoma Seed Capital Fund, Oklahoma Angel Capital Fund II, a fund managed by 'returning investor' i2E, Inc., Investment Arm. The transaction included participation from Oklahoma Medical Research Foundation, Burns & Stowers Investments LLC, Stanford University, Endowment Arm and returning investors OCA Venture Partners, LLC, Mayo Clinic Ventures, NMC Health Plc (LSE:NMC).